Evidence map›Paper›PMID 35978600›Full record

ArticleLiver cancer2022

Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.

Dongdong Xia, Wei Bai, Enxin Wang, Jiaping Li, Xiaoming Chen, Zhexuan Wang, Mingsheng Huang, Ming Huang, Junhui Sun, Weizhu Yang and 28 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. FeCurrent cancer drug targets · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Observational
  15. Article
  16. Article
  17. Article
  18. New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 14 institutions in 1 country.

Dongdong XiaDepartment of Liver Diseases and Interventional Radiology, Digestive Diseases Hospital, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China.
Wei BaiDepartment of Liver Diseases and Interventional Radiology, Digestive Diseases Hospital, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China.
Enxin WangDepartment of Liver Diseases and Interventional Radiology, Digestive Diseases Hospital, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China.
Jiaping LiDepartment of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Xiaoming ChenDepartment of Interventional Radiology, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Provincial Academy of Medical Sciences, Guangzhou, China.
Zhexuan WangDepartment of Liver Disease and Digestive Interventional Radiology, National Clinical Research Center for Digestive Disease and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
Mingsheng HuangDepartment of Interventional Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Ming HuangDepartment of Minimally Invasive International Therapy, The Third Affiliated Hospital of Kunming University, Tumor Hospital of Yunnan Province, Kunming, China.
Junhui SunDepartment of Hepatobiliary and Pancreatic Interventional Cancer, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Weizhu YangDepartment of Interventional Radiology, Fujian Medical University Union Hospital, Fuzhou, China.
Zhengyu LinDepartment of Interventional Radiology, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Jianbing WuDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Zixiang LiDepartment of Interventional Radiology, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China.
Shufa YangInterventional Medical Center of the Affiliated Hospital of Qingdao University, Qingdao, China.
Xu ZhuDepartment of Interventional Radiology, Peking University Cancer Hospital, Beijing, China.
Zaizhong ChenDepartment of Interventional Radiology, Peking University Shenzhen Hospital, Shenzhen, China.
Yanfang ZhangDepartment of Interventional Radiology, Shenzhen People's Hospital, Shenzhen, China.
Wenzhe FanDepartment of Interventional Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Qicong MaiDepartment of Interventional Radiology, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Provincial Academy of Medical Sciences, Guangzhou, China.
Rong DingDepartment of Minimally Invasive International Therapy, The Third Affiliated Hospital of Kunming University, Tumor Hospital of Yunnan Province, Kunming, China.
Chunhui NieDepartment of Hepatobiliary and Pancreatic Interventional Cancer, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Long FengDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Xueda LiDepartment of Interventional Radiology, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China.
Wukui HuangInterventional Medical Center of the Affiliated Hospital of Qingdao University, Qingdao, China.
Jun SunDepartment of Liver Disease and Digestive Interventional Radiology, National Clinical Research Center for Digestive Disease and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
Qiuhe WangDepartment of Liver Disease and Digestive Interventional Radiology, National Clinical Research Center for Digestive Disease and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
Yong LvDepartment of Liver Disease and Digestive Interventional Radiology, National Clinical Research Center for Digestive Disease and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
Xiaomei LiDepartment of Liver Diseases and Interventional Radiology, Digestive Diseases Hospital, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China.
Bohan LuoDepartment of Liver Diseases and Interventional Radiology, Digestive Diseases Hospital, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China.
Zhengyu WangDepartment of Liver Diseases and Interventional Radiology, Digestive Diseases Hospital, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China.
Jie YuanDepartment of Liver Diseases and Interventional Radiology, Digestive Diseases Hospital, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China.
Wengang GuoDepartment of Liver Diseases and Interventional Radiology, Digestive Diseases Hospital, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China.
Kai LiDepartment of Liver Disease and Digestive Interventional Radiology, National Clinical Research Center for Digestive Disease and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
Bing LiDepartment of Liver Diseases and Interventional Radiology, Digestive Diseases Hospital, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China.
Ruijun LiDepartment of Liver Diseases and Interventional Radiology, Digestive Diseases Hospital, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China.
Zhanxin YinDepartment of Liver Diseases and Interventional Radiology, Digestive Diseases Hospital, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China.
Jielai XiaDepartment of Health Statistics, Fourth Military Medical University, Xi'an, China.
Guohong HanDepartment of Liver Diseases and Interventional Radiology, Digestive Diseases Hospital, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China.
Northwest University · CNNational Clinical Research Center for Digestive Diseases · CNKunming University · CNXinjiang Medical University · CNFujian Medical University · CNGuangdong Academy of Medical Sciences · CNNanchang University · CNQingdao University · CNSun Yat-sen University · CNAir Force Medical University · CNPeking University · CNPeking University Shenzhen Hospital · CNShenZhen People’s Hospital · CNZhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma (HCC). We aimed to compare the clinical outcomes of lenvatinib plus drug-eluting beads transarterial chemoembolization (DEB-TACE) versus lenvatinib alone in real-world practice. Methods: This retrospective analysis included 142 consecutive patients who received lenvatinib plus DEB-TACE and 69 patients who received lenvatinib alone as first-line treatment from 15 Chinese academic centers from November 2018 to November 2019. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR) were evaluated by modified Response Evaluation Criteria in Solid Tumors criteria, and safety profiles were compared between the two groups. Results: The median OS and PFS were significantly longer in the combined therapy group than in the monotherapy group in whole cohort (median OS, 15.9 vs. 8.6 months, Conclusions: With well-tolerated safety, lenvatinib plus DEB-TACE was more effective than lenvatinib monotherapy in improving OS, PFS, and ORR. Thus, it may be a promising treatment for advanced HCC. Future prospective studies confirming these findings are warranted.

Indexed as

Drug-eluting beads transarterial chemoembolizationEfficacyHepatocellular carcinomaLenvatinibSafety

Identifiers

PMID35978600
PMCPMC9294948
OpenAlexW4220817213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.